Javascript must be enabled to continue!
ClickChem: Automated Conjugation Chemistry Planning for Antibody–Drug Conjugates
View through CrossRef
Antibody–drug conjugates (ADCs) require precise conjugation chemistry to covalently attach cytotoxic payloads to monoclonal antibodies while preserving antigen-binding function and pharmacokinetic stability. The selection of an appropriate conjugation strategyencompassing the reaction family, the conjugation site on the antibody, and the linker architecture—remains largely empirical, relying on iterative experimental screens that are costly and time-consuming. We present ClickChem, a computational pipeline that auto-mates conjugation chemistry selection for ADC design. The pipeline operates in six sequential stages: functional-group detection on the payload, multi-conformer solvent-accessible surface area (SASA) scoring of antibody conjugation sites, chemistry family planning across seven reaction families, linker selection from a curated library, in silico bond formation via SMIRKSbased reaction execution, and product validation through a six-layer quality-control protocol incorporating Maximum Common Substructure (MCS) analysis. A distinguishing feature of the site-scoring module is an ensemble-averaged SASA calculation that generates multiple antibody conformations through an Anisotropic Network Model (ANM) and aggregates solvent-exposure statistics across the ensemble, yielding a confidence metric that penalises residues whose accessibility fluctuates between conformations. We evaluate the pipeline on three fronts. First, we verify concordance with established clinical precedent by exercising the pipeline on the payloads and conjugation-site annotations of ten FDA-approved ADCsincluding Adcetris, Kadcyla, Enhertu, and Trodelvy—and show that the pipeline selects the conventionally employed reaction family in all ten cases (10/10 concordance). Second, we present two end-to-end case studies—MMAF and Doxorubicin conjugated to a full-length IgG surrogate (PDB: 1IGT) via heterobifunctional SPAAC–IEDDA dual-click chemistrydemonstrating handle installation, site-specific conjugation at three distinct residue types
Title: ClickChem: Automated Conjugation Chemistry Planning for Antibody–Drug Conjugates
Description:
Antibody–drug conjugates (ADCs) require precise conjugation chemistry to covalently attach cytotoxic payloads to monoclonal antibodies while preserving antigen-binding function and pharmacokinetic stability.
The selection of an appropriate conjugation strategyencompassing the reaction family, the conjugation site on the antibody, and the linker architecture—remains largely empirical, relying on iterative experimental screens that are costly and time-consuming.
We present ClickChem, a computational pipeline that auto-mates conjugation chemistry selection for ADC design.
The pipeline operates in six sequential stages: functional-group detection on the payload, multi-conformer solvent-accessible surface area (SASA) scoring of antibody conjugation sites, chemistry family planning across seven reaction families, linker selection from a curated library, in silico bond formation via SMIRKSbased reaction execution, and product validation through a six-layer quality-control protocol incorporating Maximum Common Substructure (MCS) analysis.
A distinguishing feature of the site-scoring module is an ensemble-averaged SASA calculation that generates multiple antibody conformations through an Anisotropic Network Model (ANM) and aggregates solvent-exposure statistics across the ensemble, yielding a confidence metric that penalises residues whose accessibility fluctuates between conformations.
We evaluate the pipeline on three fronts.
First, we verify concordance with established clinical precedent by exercising the pipeline on the payloads and conjugation-site annotations of ten FDA-approved ADCsincluding Adcetris, Kadcyla, Enhertu, and Trodelvy—and show that the pipeline selects the conventionally employed reaction family in all ten cases (10/10 concordance).
Second, we present two end-to-end case studies—MMAF and Doxorubicin conjugated to a full-length IgG surrogate (PDB: 1IGT) via heterobifunctional SPAAC–IEDDA dual-click chemistrydemonstrating handle installation, site-specific conjugation at three distinct residue types.
Related Results
ClickChem: Automated Conjugation Chemistry Planning for Antibody–Drug Conjugates
ClickChem: Automated Conjugation Chemistry Planning for Antibody–Drug Conjugates
Antibody–drug conjugates (ADCs) require precise conjugation chemistry to covalently attach cytotoxic payloads to monoclonal antibodies while preserving antigen-binding function and...
Antibody and antibody fragments site-specific conjugation using new Q-tag substrate of bacterial transglutaminase
Antibody and antibody fragments site-specific conjugation using new Q-tag substrate of bacterial transglutaminase
AbstractDuring the last few years Antibody-Drug Conjugates (ADCs) have become one of the most active and very promising therapeutic weapons. Lessons learned from the traditional ch...
Antibody and antibody fragments Site Specific Conjugation using New Q-tag Substrate of Bacterial Transglutaminase.
Antibody and antibody fragments Site Specific Conjugation using New Q-tag Substrate of Bacterial Transglutaminase.
Abstract
During the last few years Antibody Drug Conjugates (ADCs) have become one of the most active and very promising therapeutic weapons. Lessons learned from the tradi...
Abstract 1538: Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery
Abstract 1538: Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery
Abstract
Antibody drug conjugates (ADCs) are an effective class of cancer therapeutics which have become more prominent after eight FDA approvals in the past three y...
Abstract 4593: Glycoengineered antibodies for click chemistry applications
Abstract 4593: Glycoengineered antibodies for click chemistry applications
Abstract
Antibody-drug conjugates (ADC) hold considerable promise as anticancer agents. A critical determinant of the effectiveness of ADCs is the chemistry that is ...
Abstract 4324: Maytansinoid conjugates of a novel type III anti-CD20 antibody with potent antitumor activity.
Abstract 4324: Maytansinoid conjugates of a novel type III anti-CD20 antibody with potent antitumor activity.
Abstract
Previously identified anti-CD20 antibodies have been classified as either Type I antibodies with lipid raft and complement-dependent cytotoxicity (CDC) acti...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND
As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
Procedure for Western blot v1
Procedure for Western blot v1
Goal: This document has the objective of standardizing the protocol for Western blot. This technique allows the detection of specific proteins separated on polyacrylamide gel and t...

